Dr. Kelley is the 2017 recipient of the Bantz Petronio Translating Research Into Practice Award
Since joining the Department of Pediatrics at the IU School of Medicine in 1993, Dr, Kelley’s work has focused on translational research in DNA damage and repair, specifically, to determine how those activities can be exploited therapeutically to treat cancers and protect normal cells from DNA damage.
He has focused specifically on the enzyme called APE1 as a therapeutic target in cancers and other diseases. Dr. Kelley discovered and has been developing a specific inhibitor of APE1 which he is now translating to clinical trials. This work has also led to the creation of a biotechnology company called Apexian Pharmaceuticals, of which Dr. Kelley is the Chief Scientific Founder and Officer.
The first drug developed has recently been approved by the FDA for Phase 1 clinical trials in cancer patients scheduled to begin in 2017. The drug has potential uses in a number of cancers including ovarian, colon, bladder, pancreatic, leukemia, and other adult and pediatric cancers.
He is also exploring the use of the target APE1 and the drug to prevent a major side-effect of cancer treatments called chemotherapy-induced peripheral neuropathy (CIPN).
Dr. Kelley is committed to fast-tracking collaboration and translational research efforts in order to find more effective cancer treatments. He also mentors and encourages students, post-doctorates, fellows and junior faculty in translating their research into practice to expand the number of discoveries that help solve problems and make life better.Professor Kelley's application of a business model to support research planning and implementation is another example of how IUPUI's faculty members are TRANSLATING their RESEARCH INTO PRACTICE.
Selected Publications in IUPUIScholarWorks
With over fifty scholarly articles contributed to IUPUI's free, open access repository, Dr. Kelley has made research knowledge about the role of the DNA repair enzyme APE1/Ref-1 in cancer therapy available available to researchers, students and readers around the world.
Li, Y., Liu, X., Zhou, T., Kelley, M. R., Edwards, P., Gao, H., & Qiao, X. (2014). Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization. Redox Biology, 2, 485-494. Available from: http://hdl.handle.net/1805/4698
Kelley, M. R., Georgiadis, M. M., & Fishel, M. L. (2012). APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Current Molecular Pharmacology, 5(1), 36. Available from: http://hdl.handle.net/1805/4688
Kelley, M. R. (2011). DNA repair inhibitors: Where do we go from here?. DNA Repair, 10(11), 1183. Available from: http://hdl.handle.net/1805/4687
Fishel, M. L., Jiang, Y., Rajeshkumar, N. V., Scandura, G., Sinn, A. L., He, Y., ... & Kelley, M. R. (2011). Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth. Molecular Cancer Therapeutics, 10(9), 1698-1708. Available from: http://hdl.handle.net/1805/4685
Vasko, M. R., Guo, C., Thompson, E. L., & Kelley, M. R. (2011). The repair function of the multifunctional DNA repair/redox protein APE1 is neuroprotective after ionizing radiation. DNA Repair, 10(9), 942-952. Available from: http://hdl.handle.net/1805/4686
Kelley, M. R., Luo, M., Reed, A., Su, D., Delaplane, S., Borch, R. F., ... & Georgiadis, M. M. (2011). Functional analysis of novel analogues of E3330 that block the redox signaling activity of the multifunctional AP endonuclease/redox signaling enzyme APE1/Ref-1. Antioxidants & Redox Signaling, 14(8), 1387-1401. Available from: http://hdl.handle.net/1805/4867
Jiang, Y., Guo, C., Fishel, M. L., Wang, Z. Y., Vasko, M. R., & Kelley, M. R. (2009). Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA repair, 8(11), 1273-1282. Available from: http://hdl.handle.net/1805/4814
Tell, G., Quadrifoglio, F., Tiribelli, C., & Kelley, M. R. (2009). The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxidants & Redox Signaling, 11(3), 601-619. Available from: http://hdl.handle.net/1805/4803
Bapat, A., Fishel, M. L., & Kelley, M. R. (2009). Going ape as an approach to cancer therapeutics. Antioxidants & redox signaling, 11(3), 651-667. Available from: http://hdl.handle.net/1805/4789
Reed, A. M., Fishel, M. L., & Kelley, M. R. (2009). Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation. Future Oncology, 5(5), 713-726. Available from: http://hdl.handle.net/1805/4819
Find more free articles by Mark R. Kelley in IUPUIScholarWorks.